Press "Enter" to skip to content

Novartis gets European approval for sight therapy Luxturna

Luxturna is a one-time treatment for children and adults who have suffered impaired vision from an early age due to mutations in both copies of the RPE65 gene.

Original source:

Also Read:   Swiss tap pharmaceutical reserves as coronavirus deaths rise